ClinicalTrials.gg
Active, not recruitingNCT04546750VINCIUpdated Jun 29, 2026

Prospective Cohort Study for Varicose Veins Incidence and Natural Course

An observational study in Varicose Veins of Lower Limb, Thromboses, Venous and Venous Insufficiency, sponsored by Russian Phlebological Association. Active, not recruiting at 1 site in Russia. Open to participants aged 10 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Russian Phlebological Association · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
10 Years and older
Sex
All
01

Study summary

A prospective study of individuals without varicose veins and who have primary varicose veins to assess the morbidity, risk factors and natural course of chronic lower limb vein disease.

Read the detailed description

Multicenter prospective cohort observational study based on a termless epidemiological registry. Periodic inspection and collection of data from the subjects is carried out annually, in the last quarter of the current year. Patient data is recorded in a digital database and is constantly updated

02

Conditions studied

  • Varicose Veins of Lower Limb
  • Thromboses, Venous
  • Venous Insufficiency
03

In context

Venous Thrombosis

785 studies on the registry are indexed under Venous Thrombosis; 110 are open to participants now.

This study's planned enrollment of 100 is below the median of 301 across 274 observational studies indexed under Venous Thrombosis.

Browse Venous Thrombosis studies →

Lead sponsor

Russian Phlebological Association is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The main cohort is formed from those who do not have varicose veins, who are affected by different factors that we register (various physical activities, the presence or absence of pregnancy, etc.).

An additional cohort is formed from those who have varicose veins at the time of inclusion.

The goal is to track the natural evolution (progression) of the disease, to evaluate the incidence and risk factors of complications.

An extremely important criterion for the formation of the study population is the possibility to control the lower legs veins of observed individuals by a qualified vascular specialist. To date, a qualitative assessment of veins according to the CEAP classification is a weak point in longitudinal epidemiological studies.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A family members of the researcher (spouse, childrens, brothers and sisters, parents) or the researcher himself
  • The possibility of annual clinical and ultrasound assessment of the venous system of the observed individuals

Exclusion criteria

Exclusion Criteria:

  • Any invasive treatment of the chronic venous disorder in anamnesis
  • Venous thrombosis in the anamnesis or at the time of inclusion
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients without Varicose Veins

    Individuals who do not have varicose veins of lower legs: C0, C1 classes according to Clinical, Etiologic, Anatomic and Pathophysiologic classification (CEAP)

  • Patients with Varicose Veins

    Individuals who have varicose veins of lower legs: C2 Ep class according to Clinical, Etiologic, Anatomic and Pathophysiologic classification (CEAP)

06

What researchers measure

Primary outcomes

  1. Incidence of primary varicose veins

    Number of Participants with the first identified varicose veins (class C2 according to CEAP classification)

    Time frame: 1 year

Secondary outcomes

  1. Progression of primary varicose veins

    The presence of varicose veins in new areas of the lower extremites (each limb is divided into 8 areas: thigh - anterior, posterior, medial, lateral area; lower leg - anterior, posterior, medial, lateral area)

    Time frame: 1 year

  2. Incidence of chronic venous insufficiency

    Number of participants with the first identified sign of chronic venous insufficiency (venous edema, venous eczema, hyperpigmentation of the skin, lipodermatosclerosis, venous ulcer)

    Time frame: 1 year

  3. Incidence of superficial vein thrombosis

    Number of participants with first episode of superficial vein thrombosis

    Time frame: 1 year

  4. Incidence of reticular and telangiectatic leg veins

    Number of Participants with the first identified eticular and telangiectatic leg veins ((class C1 according to CEAP classification)

    Time frame: 1 year

  5. Progression of reticular and telangiectatic leg veins

    The presence of reticular and telangiectatic leg veins in new areas of the lower extremites (each limb is divided into 8 areas: thigh - anterior, posterior, medial, lateral area; lower leg - anterior, posterior, medial, lateral area)

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for Sep 2030, 120 months after the start.

Of 103 non-industry observational studies under Venous Thrombosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 99. This study's planned 120 months is above that.

Counting every sponsor, half of 127 studies reached it within 46 months; a quarter within 21 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2020
First posted
Sep 14, 2020
StartActual
Sep 1, 2020
Primary completionEst.
Sep 2030
CompletionEst.
Sep 2030
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04546750
Lead sponsor
Russian Phlebological Association
Responsible party
Sponsor
First posted
Sep 14, 2020
Start date
Sep 1, 2020
Primary completion
Sep 2030 (estimated)
Completion
Sep 2030 (estimated)
Last update
Jun 29, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion